Patents by Inventor Shansong ZHENG

Shansong ZHENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20240034743
    Abstract: Provided are a class of compounds, represented by formula (I??), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds of the present invention to treat cell proliferative diseases, such as cancers.
    Type: Application
    Filed: April 13, 2021
    Publication date: February 1, 2024
    Inventors: Shansong ZHENG, Wei DENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
  • NOVEL AMINOPYRIMIDINE EGFR INHIBITOR
    Publication number: 20230219986
    Abstract: The present invention provides a novel aminopyrimidine compound as a fourth-generation EGFR (T790M/C797S mutation) selective inhibitor, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compound, and a method for treating a cell proliferative disease, such as a cancer, by using the compound of the present invention.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 13, 2023
    Applicants: QILU PHARMACEUTICAL CO., LTD., QILU PHARMACEUTICAL CO., LTD.
    Inventors: Wei DENG, Shansong ZHENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
  • TRICYCLIC COMPOUNDS AS EGFR INHIBITORS
    Publication number: 20230192734
    Abstract: Provided are a class of compounds, represented by formula (I??), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds of the present invention to treat cell proliferative diseases, such as cancers.
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Inventors: Shansong ZHENG, Wei DENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
  • Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
    Patent number: 10053477
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 21, 2018
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong Ding, Minghui Zhang, Shuhui Chen, Xile Liu, Yidong Zhu, Chuanwen Fan, Baoping Zhao, Long Zhang, Yingying Yang, Qingmei Zheng, Shansong Zheng, Haiwen Wan, Jinqing Hu
  • SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE
    Publication number: 20170129909
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 29, 2015
    Publication date: May 11, 2017
    Applicant: QUILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong DING, Minghui ZHANG, Shuhui CHEN, Xile LIU, Yidong ZHU, Chuanwen FAN, Baoping ZHAO, Long ZHANG, Yingying YANG, Qingmei ZHENG, Shansong ZHENG, Haiwen WAN, Jinqing HU